BioAge Labs (BIOA) shares slumped 70% pre-bell Monday after the company said late Friday it is terminating a phase 2 trial of its obesity drug candidate following observations of liver transaminitis.
Universe Pharmaceuticals (UPC) shares fell 54% after the company unveiled a $15 million registered direct offering of ordinary shares and warrants.
Radiopharm Theranostics (RADX) shares dropped 25% after Friday's 7% increase.
Palmer Square Capital (PSBD) shares retreated 18% following a 1.3% gain in the previous session.
Forrester Research (FORR) shares were down 17% following a muted session.